Patients and techniques Soon after receiving authorization through the EORTC Impartial Information Monitoring Board, the first 2,1000 patients along with operable unifocal invasive cancers of the breast (5�C30?mm) and also technically unfavorable lymph nodes signed up on the AMAROS trial have been analyzed. The analysis design of the AMAROS trial can be revealed in #links# Fig.?1. Patients are not